Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 March 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Effect of the GABAB agonist baclofen on symptoms of GERD

The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in patients with GERD, finds a research team in the April issue of Gut.

News image

fiogf49gjkf04

The gamma-aminobutyric acid (GABAB) agonist baclofen reduces reflux episodes in the first 3 postprandial hours. This occurs in both patients with gastro-esophageal reflux disease (GERD) and in normal controls.

In this study, researchers from Italy assessed acute and chronic administration of baclofen on 24-hour pH metry and symptoms in GERD patients and normal controls.

In the acute study, the team assessed 28 patients with GERD, and none or mild esophagitis at endoscopy. They also assessed 15 controls.

Baclofen or placebo were administered for 24 hours in a double blinded manner.

In the acute study, gastric pH increased significantly in both groups.
Gut

Subjects underwent esophageal and gastric 48-hour pH metry.

In the chronic study, 16 GERD patients received baclofen (10 mg 4 times daily) or placebo for 4 weeks.

The team evaluated 24-hour esophageal pH metry and reflux symptom scores before and after treatment.

In the acute study, researchers found that the number of reflux episodes and percent of time with pH < 4 was significantly lower after baclofen in both GERD patients and controls.

In addition, gastric pH increased significantly in both groups.

In the chronic study, the team found that 4 weeks after initial administration of baclofen, the number of reflux episodes and percentage of time with pH < 4 significantly decreased in all GERD patients.

In addition, symptom scores significantly improved after treatment with baclofen.

Profs. Ciccaglione and Marzio concluded, "The GABAB agonist baclofen reduces 24 hour gastro-esophageal reflux and increases gastric pH in GERD patients and controls".

"When given for 1 month to GERD patients, baclofen reduces esophageal acid refluxes and significantly improves symptoms."

"Baclofen may be useful in the therapy of GERD."

Gut 2003; 52: 464-70
14 March 2003

Go to top of page Email this page Email this page to a colleague

 24 March 2017 
Prevalence of undiagnosed celiac disease
 24 March 2017 
MRI for local staging of colon cancer
 24 March 2017 
In-office communication about ulcerative colitis
 23 March 2017 
H. pylori and GERD in children
 23 March 2017 
Prespectives on the management of fecal incontinence
 23 March 2017 
Suspected nonceliac gluten sensitivity
 22 March 2017 
Abdominal visceral fat and new erosive esophagitis
 22 March 2017 
Role of microbiota in colorectal surgery
 22 March 2017 
Disease activity in eosinophilic esophagitis
 21 March 2017 
Hepatitis C virus–related hepatic myelopathy
 21 March 2017 
Global trends in colorectal cancer mortality
 21 March 2017 
Pain in pancreatic cancer
 20 March 2017 
Metastasis in human colorectal cancer
 20 March 2017 
Fistula treatment of Crohn’s disease
 20 March 2017 
NASH treatment and MRI
 17 March 2017 
Acute liver failure in Scotland
 17 March 2017 
Microbiota in colorectal cancer 
 17 March 2017 
Among Persons with IBD
 16 March 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 16 March 2017 
IBD disability index
 16 March 2017 
Transition readiness scores in adolescents with IBD
 15 March 2017 
European consensus on fecal microbiota transplantation 
 15 March 2017 
Hepatocellular carcinoma in the USA 
 15 March 2017 
Hospital readmission for ulcerative colitis
 14 March 2017 
Cardiovascular diseases risk in Barrett's
 14 March 2017 
Assessment of competence in colonoscopy
 14 March 2017 
Cholecystectomy to prevent recurrent pancreatitis
 13 March 2017 
Gallstone disease after colectomy for ulcerative colitis
 13 March 2017 
Achalasia in Chicago since high-resolution manometry
 13 March 2017 
Vedolizumab exposure in pregnancy
 10 March 2017 
Thiopurine therapy in IBD
 10 March 2017 
Complications in advanced fibrosis in Hep C eradication
 10 March 2017 
Intragastric balloons for obesity-related co-morbidities
 09 March 2017 
Intestinal tuberculosis vs Crohn's disease
 09 March 2017 
Predictors of relapse in children with IBD
 09 March 2017 
Direct-acting antiviral regimen for Hep C genotype 3 
 08 March 2017 
Sterile fecal filtrate transfer for C. diff
 08 March 2017 
Drug-induced liver injury
 08 March 2017 
Pharmacotherapy for alcohol dependence
 07 March 2017 
Psychotropic drugs in functional dyspepsia
 07 March 2017 
Vagus nerve and appetite regulation
 07 March 2017 
Gastrointestinal involvement in systemic sclerosis
 06 March 2017 
Small bowel abnormalities in IBS 
 06 March 2017 
Treatment response in NASH with MRI
 06 March 2017 
Intestinal bacterial overgrowth and PPIs in children
 03 March 2017 
Alcohol and risk of gallstone disease
 03 March 2017 
Smoking at colon cancer diagnosis influences survival
 03 March 2017 
Improvements in Crohn’s Disease outcomes over time
 02 March 2017 
Surviving sepsis guidelines
 02 March 2017 
Tenofovir and Hep B transmission in pregnancy
 02 March 2017 
Diagnosis of pediatric IBD 
 01 March 2017 
Healthcare utilization amonth IBD Veterans
 01 March 2017 
Complications after ileocecal resection in Crohn’s
 01 March 2017 
Fecal microbiotica transplnantation

 28 February 2017 
Smoking and cancer-specific survival in colon cancer
 28 February 2017 
ALT levels and all-cause mortality
 28 February 2017 
American Gastroenterological Association for acute liver failure
 27 February 2017 
Hep B cure research
 27 February 2017 
Elemental diet in adult eosinophilic esophagitis patients
 27 February 2017 
Eluxadoline in IBS-diarrhea

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us